| Day-to-day and within-day biological variation of cell-free DNA AT Madsen, JA Hojbjerg, BS Sorensen, A Winther-Larsen EBioMedicine 49, 284-290, 2019 | 54 | 2019 |
| MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR-mutated, NSCLC HCC827 cells KR Jakobsen, C Demuth, AT Madsen, D Hussmann, J Vad-Nielsen, ... Oncogenesis 6 (4), e307-e307, 2017 | 54 | 2017 |
| The anionic biosurfactant rhamnolipid does not denature industrial enzymes JK Madsen, R Pihl, AH Møller, AT Madsen, DE Otzen, KK Andersen Frontiers in microbiology 6, 292, 2015 | 50 | 2015 |
| Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients A Winther-Larsen, C Demuth, J Fledelius, AT Madsen, K Hjorthaug, ... British journal of cancer 117 (5), 704-709, 2017 | 47 | 2017 |
| Increased PD-L1 expression in erlotinib-resistant NSCLC cells with MET gene amplification is reversed upon MET-TKI treatment C Demuth, MN Andersen, KR Jakobsen, AT Madsen, BS Sørensen Oncotarget 8 (40), 68221, 2017 | 35 | 2017 |
| Biological variation of serum neurofilament light chain CVB Hviid, AT Madsen, A Winther-Larsen Clinical Chemistry and Laboratory Medicine (CCLM) 60 (4), 569-575, 2022 | 27 | 2022 |
| Genomic Profiling of Circulating Tumor DNA Predicts Outcome and Demonstrates Tumor Evolution in ALK-Positive Non-Small Cell Lung Cancer Patients AT Madsen, A Winther-Larsen, T McCulloch, P Meldgaard, BS Sorensen Cancers 12 (4), 947, 2020 | 26 | 2020 |
| IGF1R depletion facilitates MET-amplification as mechanism of acquired resistance to erlotinib in HCC827 NSCLC cells. D Hussmann, AT Madsen, KR Jakobsen, Y Luo, BS Sorensen, AL Nielsen Oncotarget 8 (20), 33300, 2017 | 25 | 2017 |
| Inflammatory Cytokines and ctDNA Are Biomarkers for Progression in Advanced-Stage Melanoma Patients Receiving Checkpoint Inhibitors JG Pedersen, AT Madsen, KR Gammelgaard, N Aggerholm-Pedersen, ... Cancers 12 (6), 1414, 2020 | 21 | 2020 |
| A method for treatment monitoring using circulating tumour DNA in cancer patients without targetable mutations C Demuth, A Winther-Larsen, AT Madsen, P Meldgaard, BS Sorensen Oncotarget 9 (57), 31066, 2018 | 18 | 2018 |
| Intra‐individual variation of circulating tumour DNA in lung cancer patients JA Hojbjerg, AT Madsen, HH Schmidt, SF Sorensen, M Stougaard, ... Molecular Oncology 13 (10), 2098-2106, 2019 | 16 | 2019 |
| The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment C Demuth, AT Madsen, B Weber, L Wu, P Meldgaard, BS Sorensen BMC cancer 18 (1), 1-5, 2018 | 16 | 2018 |
| Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies MC Pulanco, AT Madsen, A Tanwar, DT Corrigan, X Zang Cellular & Molecular Immunology, 1-20, 2023 | 11 | 2023 |
| Day-to-day and within-day biological variation of cell-free DNA. EBioMedicine 2019; 49: 284–90 AT Madsen, JA Hojbjerg, BS Sorensen, A Winther-Larsen Author and article information From the Division of Maternal-Fetal Medicine …, 0 | 8 | |
| Short-term biological variation of serum glial fibrillary acidic protein SH Christensen, CVB Hviid, AT Madsen, T Parkner, A Winther-Larsen Clinical Chemistry and Laboratory Medicine (CCLM) 60 (11), 1813-1819, 2022 | 5 | 2022 |
| Functional Contribution of Cancer-Associated Fibroblasts in Glioblastoma PM Galbo Jr, Y Liu, M Peng, Y Wei, AT Madsen, S Graff, C Montagna, ... bioRxiv, 2022.04. 07.487495, 2022 | 2 | 2022 |
| P2. 03-19 Co-Targeting PIM Kinase to Overcome MET Amplified Resistance to EGFR TKIs in NSCLC AT Madsen, G Moore, N Simon, A Mahon, S Cuffe, S Finn, M O'Neill, ... Journal of Thoracic Oncology 14 (10), S690, 2019 | 1 | 2019 |
| P3. 02-050 Mechanisms of Acquired Resistance to the ALK Inhibitor Lorlatinib in ALK-Rearranged NSCLC Cell Lines A Madsen, K Jakobsen, C Demuth, B Sørensen Journal of Thoracic Oncology 12 (11), S2255, 2017 | 1 | 2017 |
| Short-term biological variation of plasma uracil in a Caucasian healthy population A Winther-Larsen, AT Madsen, PH Nissen, E Hoffmann-Lücke, E Greibe Clinical Chemistry and Laboratory Medicine (CCLM), 2023 | | 2023 |
| Butyrophilins 3A as an immune checkpoint and a therapeutic target in hematological malignancies Y Li, X Ren, Y Wei, M Peng, H Wang, MC Pulanco, CD Nishimura, ... Cancer Research 82 (12_Supplement), 6395-6395, 2022 | | 2022 |
